Skip to main content
Premium Trial:

Request an Annual Quote

CombiMatrix to Invest $4M in Cancer Drug Company Leuchemix

NEW YORK, Oct. 4 (GenomeWeb News) - CombiMatrix will take a 33 percent stake in cancer drug discovery firm Leuchemix, it parent company Acacia Research said today.

 

In exchange for equity ownership in the form of preferred stock, CombiMatrix will pay Leuchemix a total of $4 million in quarterly installments over the next two years.

 

Leuchemix is developing a series of small molecules that have shown efficacy against various leukemias and solid tumors in animal models. The company plans to file its first investigational new drug application in 2005.

The Scan

US Booster Eligibility Decision

The US CDC director recommends that people at high risk of developing COVID-19 due to their jobs also be eligible for COVID-19 boosters, in addition to those 65 years old and older or with underlying medical conditions.

Arizona Bill Before Judge

The Arizona Daily Star reports that a judge is weighing whether a new Arizona law restricting abortion due to genetic conditions is a ban or a restriction.

Additional Genes

Wales is rolling out new genetic testing service for cancer patients, according to BBC News.

Science Papers Examine State of Human Genomic Research, Single-Cell Protein Quantification

In Science this week: a number of editorials and policy reports discuss advances in human genomic research, and more.